Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 20:2018:9616234.
doi: 10.1155/2018/9616234. eCollection 2018.

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Ossama Ashraf Ahmed  1 , Eslam Safwat  1 , Mohamed Omar Khalifa  2 , Ahmed I Elshafie  1 , Mohamed Hassan Ahmed Fouad  1 , Mohamed Magdy Salama  1 , Gina Gamal Naguib  1 , Mohamed Mahmoud Eltabbakh  2 , Ahmed Fouad Sherief  2 , Sherief Abd-Elsalam  3
Affiliations

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Ossama Ashraf Ahmed et al. Int J Hepatol. .

Abstract

Background and aims: As indicated by the World Health Organization (WHO), Egypt is positioned as the country with the world's highest prevalence of Hepatitis C virus (HCV). HCV is transmitted through unexamined blood transfusions, different employments of syringes, and poor cleansing, as per the WHO. Our study aimed at screening and management of chronic hepatitis C genotype 4 infected patients in Bardeen village, Sharkeya Governorate, Egypt, with Sofosbuvir plus Daclatasvir, as well as estimating the safety and efficacy of that regimen.

Methods: Screening of adult patients in Bardeen village was done from March 2016 till November 2016 using hepatitis C virus antibodies by third-generation ELISA testing. Positive results were confirmed by PCR. Patients eligible for treatment received Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virologic response at 12 weeks following the end of treatment (SVR 12).

Results: Out of 2047 subjects screened for hepatitis C virus, 249 (12.2%) showed positive results. 221 out of those 249 subjects (88.7%) had detectable RNA by PCR. Treatment of eligible patients (183 patients) with Sofosbuvir plus Daclatasvir for 12 weeks resulted in 96% achievement of sustained virologic response at week 12. Adverse events were tolerable.

Conclusion: Sofosbuvir plus Daclatasvir regimen is safe and effective for treatment of chronic hepatitis C Genotype 4 infected patients with minimal adverse events. HCV eradication program implemented in Egypt can be a model for other countries with HCV and limited resources. The availability of generic drugs in Egypt will help much in eradication of the virus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Analysis of causes of deferral from the current study.
Figure 3
Figure 3
Adverse events for Sofosbuvir/Daclatasvir regimen.
See this image and copyright information in PMC

References

    1. Gower E., Estes C. C., Hindman S., Razavi-Shearer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus. Journal of Hepatology. 2014;61(supplement 1):S45–S57. doi: 10.1016/j.jhep.2014.07.027. - DOI - PubMed
    1. Aly Abd Elrazek A. E. M., Bilasy S. E., Elbanna A. E. M., Elsherif A. E. A. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (United States) 2014;93(28):p. e204. doi: 10.1097/MD.0000000000000204. - DOI - PMC - PubMed
    1. Elwan N., Elfert A., Abd-Elsalam S., et al. Study of hepatic steatosis index in patients with chronic HCV infection. International Journal of Current Microbiology and Applied Sciences. 2016;5(5):266–279. doi: 10.20546/ijcmas.2016.505.029. - DOI
    1. Abd-Elsalam S., Sharaf-Eldin M., Soliman S., Elfert A., Badawi R., Ahmad Y. K. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Archives of Virology. 2017:1–6. doi: 10.1007/s00705-017-3573-0. - DOI - PubMed
    1. Ahmed O. A., Kaisar H. H., Hawash N., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of egyptian patients with hepatitis C virus infection. Infectious Disorders—Drug Targets. 2017;17(2):95–100. doi: 10.2174/1871526517666170417143216. - DOI - PubMed

LinkOut - more resources